机器学习用于感染病临床决策支持:应用现状叙述性综述
本叙述性综述检索截至2019年7月的多数据库文献,汇总了60个面向感染病临床决策支持的机器学习系统(ML-CDSS)。这些系统主要针对细菌感染(37个,62%),聚焦感染诊断(20个,33%)与脓毒症预测或分层(18个,30%);95%仅报告性能指标,仅5%在临床实践中评估。
要点
- 60个ML-CDSS中62%针对细菌感染,33%用于感染诊断,30%用于脓毒症预测或分层。
- 88%的ML-CDSS基于高收入国家数据开发,仅12%使用中低收入国家数据。
- 95%的评估仅限灵敏度、特异度等性能指标,仅5%纳入临床实践数据。
核心结论
- 综述共识别60个感染病ML-CDSS,覆盖诊断、分类、结局预测与抗菌药物管理,但临床实践评估严重不足。
研究设计与样本
- 叙述性综述,检索MEDLINE/PubMed、EMBASE、Google Scholar、biorXiv、ACM Digital Library、arXiV与IEEE Xplore,截至2019年7月。
主要发现
- 37个(62%)针对细菌感染,10个(17%)针对病毒感染,9个(15%)针对结核,4个(7%)针对任意类型感染。
- 20个(33%)用于感染诊断,18个(30%)用于脓毒症预测、早期发现或分层,13个(22%)用于治疗反应预测。
- 4个(7%)预测抗生素耐药,3个(5%)选择抗生素方案,2个(3%)选择联合抗逆转录病毒治疗。
- 开发场景包括重症监护病房24个(40%)、感染病会诊15个(25%)、内科或外科病房13个(20%)、急诊4个(7%)、初级保健3个(5%)、抗菌药物管理1个(2%)。
临床怎么用
- 现有ML-CDSS多用于重症与感染病会诊场景的感染诊断和脓毒症风险分层,但尚无充分临床实践证据支持常规使用。
局限性
- 多数系统仅基于高收入国家数据开发,缺乏初级保健与中低收入国家数据;评估多限于性能指标,临床影响未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Machine learning (ML) is a growing field in medicine. This narrative review describes the current body of literature on ML for clinical decision support in infectious diseases (ID). OBJECTIVES: We aim to inform clinicians about the use of ML for diagnosis, classification, outcome prediction and antimicrobial management in ID. SOURCES: References for this review were identified through searches of MEDLINE/PubMed, EMBASE, Google Scholar, biorXiv, ACM Digital Library, arXiV and IEEE Xplore Digital Library up to July 2019. CONTENT: We found 60 unique ML-clinical decision support systems (ML-CDSS) aiming to assist ID clinicians. Overall, 37 (62%) focused on bacterial infections, 10 (17%) on viral infections, nine (15%) on tuberculosis and four (7%) on any kind of infection. Among them, 20 (33%) addressed the diagnosis of infection, 18 (30%) the prediction, early detection or stratification of sepsis, 13 (22%) the prediction of treatment response, four (7%) the prediction of antibiotic resistance, three (5%) the choice of antibiotic regimen and two (3%) the choice of a combination antiretroviral therapy. The ML-CDSS were developed for intensive care units (n = 24, 40%), ID consultation (n = 15, 25%), medical or surgical wards (n = 13, 20%), emergency department (n = 4, 7%), primary care (n = 3, 5%) and antimicrobial stewardship (n = 1, 2%). Fifty-three ML-CDSS (88%) were developed using data from high-income countries and seven (12%) with data from low- and middle-income countries (LMIC). The evaluation of ML-CDSS was limited to measures of performance (e.g. sensitivity, specificity) for 57 ML-CDSS (95%) and included data in clinical practice for three (5%). IMPLICATIONS: Considering comprehensive patient data from socioeconomically diverse healthcare settings, including primary care and LMICs, may improve the ability of ML-CDSS to suggest decisions adapted to various clinical contexts. Currents gaps identified in the evaluation of ML-CDSS must also be addressed in order to know the potential impact of such tools for clinicians and patients.
引用
- Peiffer-Smadja N, Rawson TM, Ahmad R, et al. Machine learning for clinical decision support in infectious diseases: a narrative review of current applications. Clin Microbiol Infect. 2019. PMID: 31539636. doi:10.1016/j.cmi.2019.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。